Assessing the Promise of Liquid Biopsy to Enable Detection of Druggable Genomic Alterations Using Targeted NGS Assays Optimized for CTCs and ctDNAMonday, 23 March 2015 at 15:30 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) could enable characterization of druggable targets in blood samples from patients with cancer, especially when conventional biopsies are unobtainable, to inform selection of targeted therapies and provide insights into systemic disease. To assess the clinical utility of the liquid biopsy, we have genomically profiled primary resections, metastatic biopsies, ctDNA and CTCs from the same patients with a diverse spectrum of solid tumors. |